Sponsor Dossier
Sun Pharma
Sponsor Dossier for Sun Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: AATORVASTATIN
- Brand: ABISART
- Brand: ACICLOVIR
- Brand: AMLODIPINE
- Brand: AMOXYCILLIN GENERICHEALTH
- Brand: AMPHOTERICIN LIPOSOMAL
- Brand: APO-DIAZEPAM
- Brand: ARIPENA
About
Sun Pharma is an Australian Private Company with ABN 17 110 871 826, registered in NSW. The entity is currently active and registered for GST.
Portfolio
Sun Pharma has 124 brands on the ARTG, of which 50 are indexable and 45 carry a Product Information document. 39 brands are PBS-listed, 8 have a PBAC outcome on record, and 5 have an AusPAR on record. Notable brands include AATORVASTATIN, ABISART, ACICLOVIR, AMLODIPINE, AMOXYCILLIN GENERICHEALTH, AMPHOTERICIN LIPOSOMAL, APO-DIAZEPAM, ARIPENA, ARIPIPRAZOLE, ATORVASTATIN, ATORVATOR, BANSEP.
Therapeutic focus
— Cardiology: 26 brands — Infectious Disease: 21 brands — Gastroenterology: 14 brands — Psychiatry: 12 brands — Neurology: 11 brands — Oncology: 11 brands — Endocrinology: 8 brands — Reproductive Health: 5 brands — Musculoskeletal: 4 brands — Haematology: 3 brands — Pain Management: 3 brands — Dermatology: 2 brands — Hepatology: 1 brand — Respiratory: 1 brand — Ophthalmology: 1 brand — Immunology: 1 brand
PBS footprint
39 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2026-03-01, across 8 brands with a PBAC outcome on record. The latest AusPAR is 2024-08-21, across 5 brands with an AusPAR on record.